Growth arrest specific 6 ameliorated inflammation and portal pressure through activating efferocytosis in cholestasis and portal hypertension

Figure 6 Recombinant growth arrest specific 6 ameliorated 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced portal hypertension without alleviation of fibrosis. A: The representative images of liver sections stained with hematoxylin & eosin, Sirius Red, Masson, or by immunohistochemical with primary antibody against CK19 between two groups; B: The portal pressures of 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) mice treated with vehicle or recombinant growth arrest specific 6; C: Transcription levels of fibrosis genes including Col1a1 and Acta2 measured by qRT-PCR; D: Western blotting analysis of intrahepatic vascular resistance (p-eNOS and t-eNOS) and fibrosis (Col1a1 and α-SMA) in liver of DDC mice; E: The quantifications of Masson- or Sirius Red-stained area, and numbers of CK19⁺ cholangiocytes; F: Quantitative analysis of western blotting in panel (D). ^aP < 0.05, ^bP < 0.01. H&E: Hematoxylin & eosin; DDC: Diethoxycarbonyl-1,4-dihydrocollidine; rGas6: Recombinant growth arrest specific 6.